, the use of chemotherapy for early stage disease has become more commonplace and the use of radiotherapy alone has declined in many centres. Chemotherapy alone or in combination with radiotherapy is now considered by most authorities to be the treatment of choice for early stage disease (Gaynor & Fisher, 1990) .
The efficacy of radiotherapy for patients found to have stage I disease after meticulous staging including laparotomy has been documented (Vokes et al., 1985; Levitt et al., 1985) but few centres would now regard staging laparotomy as a necessary investigation in the assessment of intermediate grade NHL. The use of radiotherapy for clinically staged early disease has been tempered by reports of inadequate salvage by chemotherapy of patients relapsing after radiotherapy alone (Vokes et al., 1985; Monfardini et al., 1980; Kaminski et al., 1986; Armitage & Wen, 1987; Hallahan et al., 1989; Richards et al., 1989 (Jacobsen et al., 1988; Tedeschini et al., 1990) . The histology of each case was reviewed and classified according to the Working Formulation (Non-Hodgkin's Lymphoma Classification Project, 1982) . Histological groups included were diffuse small cleaved (DSC), follicular large cell (FLC), diffuse mixed (DM), and diffuse large cell (DLC).
All cases were staged according to the Ann Arbor criteria (Carbone et al., 1971 Responses were classified according to UICC criteria, relapse free survival was calculated from the date of docu-mentation of complete remission (CR) until date of last follow-up or death and overall survival was calculated from date of presentation to this unit until death or last follow-up.
The survival curves were compared according to the log-rank method (Peto et al., 1977 The most common histological sub-type was diffuse large cell (present in 65%) and systemic symptoms were present in only two patients. The overall median duration of follow-up is 30 months (range 3-119).
Thirty of the 43 patients had non-bulky disease after biopsy and were treated with involved-field radiotherapy. Twenty-nine (97%) of these 30 radiotherapy patients achieved a CR. The remaining patient (an 84 year old man) progressed during radiotherapy and was considered unsuitable for combination chemotherapy. He was treated with chlorambucil but died of lymphoma. Two patients with bulky disease were also treated with radiotherapy as they were considered medically unfit to receive chemotherapy. Both patients achieved a CR following radiotherapy, but relapsed and died of lymphoma 12 and 15 months after presentation.
Thirteen (42%) of the 31 patients achieving CR with radiotherapy have relapsed at a median time interval of 5 months from the date of CR. With the exception of one patient with diffuse small cleaved histology in whom relapse occurred 54 months from CR, all other relapses occurred within 15 months of completing treatment. Ten (77%) of these 13 patients attained a second CR following salvage chemotherapy and this has been maintained in eight patients with a median follow-up of 37 months (range 6-83 months) from the time of relapse. Four of the remaining five patients (including the two patients with bulky disease) are dead of lymphoma and the 5th patient is alive with disease.
The total radiotherapy dose was 35 Gy in 14 patients, 40 Gy in 10 patients and 45 Gy in two patients. Five patients received less than the planned total dose. Of these five patients, one progressed on treatment (after 16Gy) and the remaining four patients received 30Gy. Two of these four patients are in continuous CR at 26 + and 28 + months respectively. One patient relapsed after 11 months and is in CR 39 + months following salvage chemotherapy. The remaining patient, aged 84, relapsed and died of lymphoma. Nodal + extranodal site -3 13 aOne in-field; three in adjacent nodes; one in transdiaphragmatic site. bBone, two; tonsil, one; liver, one; skin, one. respectively (Kaminski et al., 1986; Peckham et al., 1975; Chen et al., 1979; Lamb et al., 1984; Mauch et al., 1985) .
Many of these studies included stage II patients. In pathological stage I patients treated with radiotherapy alone the freedom from relapse rates are between 66-100% and the overall survival rates at 5 years vary from 73-100% (Levitt et al., 1985; Hallshan et al., 1989; Lester et al., 1982; Hoppe et al., 1985) . The radiotherapy fields used varied between and within these studies. Although involved field radiotherapy was used in some patients, many received extended field, whole abdominal or total nodal irradiation. Three of our patients treated with involved field radiotherapy relapsed in adjacent nodal sites (see Table II ). These patients may have benefited from extended field radiotherapy but overall survival in this group was still excellent. CR. Miller and Jones (1983) (Vokes et al., 1985; Bitran et al., 1977) . It is known that between 10-24% of clinical stage I and II patients will have intra-abdominal disease detected at staging laparatomy (Hallahan et al., 1987; Lester et al., 1982; Carde et al., 1984) . In view of the significant number of patients who cannot undergo laparotomy for other medical reasons, the morbidity and mortality of the procedure, and the delay in initiating therapy this approach is impractical and has not been practised widely.
The central concern with administering local radiotherapy alone is whether combination chemotherapy can salvage clinically staged patients when occult disseminated disease progresses. Many groups have reported variable chemotherapy salvage results after radiotherapy. Carde et al. (1984) in an EORTC randomised trial investigating the value of adding CVP chemotherapy to radiotherapy salvaged all patients relapsing after radiotherapy alone and as a result there was no survival difference between the two arms. Hallahan et al. (1989) reported 7/10 CR's to salvage chemotherapy but only one was durable. Most other series have reported CR salvage rates of between 20% and 50% (Monfardini et al., 1980; Kaminski et al., 1986; Armitage & Wen, 1987; Richards et al., 1989; Lamb et al., 1984 (Vokes et al., 1985; Monfardini et al., 1980; Kaminski et al., 1986; Hallahan et al., 1989; Peckham et al., 1975; Lamb et al., 1984; Kantarjian et al., 1984; Reddy et al., 1989) .
There is evidence to suggest that the initial site of disease (i.e. extranodal vs nodal) may also be prognostically important in NHL. A proportion of cases of extranodal lymphoma may be cured by surgery alone (Rudders et al., 1978; Freeman et al., 1972; Hagberg et al., 1989) . Patients with localised involvement of gut-associated lymphoid tissue (Rudders et al., 1978; Gospodarowicz et al., 1987) are reported to have a better prognosis than patients with other extranodal sites affected. Patients with Waldeyer's ring involvement (Mill et al., 1980) , primary brain lymphoma (Littman et al., 1975; Pollack et al., 1989) and lymphoma of the testis (Duncan et al., 1980; Doll et al., 1986; Martenson et al., 1988) have been reported to have an inferior outcome. The inclusion of cases of extranodal lymphoma in reports of the management of early stage NHL may obscure or alter the efficacy of treatment for patients with nodal disease alone. We have therefore excluded cases of extranodal lymphoma from this series as they may be best managed on an individual site by site basis.
Bulky disease has been identified as an adverse prognostic factor in some series (Kaminski et al., 1986; Hagberg et al., 1989; Horwich et al., 1988; Mackintosh et al., 1988; Prestidge et al., 1988; Shigematsu et al., 1988) , but not others (Kantarjian et al., 1984; Jones et al., 1989; Taylor et al., 1988) . We selected >5 cm after surgical biopsy as representing bulky disease and chose to treat those patients with combination chemotherapy, utilising radiotherapy for non-bulky cases. Other groups have chosen 7 cm or 10 cm as their cut-off dimension and it has not always been clear whether this measurement represented pre-or post-surgical size. We have not used combined modality therapy for bulky disease and despite six of our chemotherapy patients having > 1O cm masses all have attained a CR and none have relapsed.
However median follow-up is only 25 months for the chemotherapy group and the numbers are small.
As acceptable survival can be achieved by either radiotherapy or chemotherapy (with or without radiotherapy) in patients with stage I nodal NHL other factors may influence treatment decisions. The choice of treatment may be dictated by patient preference or anticipated side effects of therapy. For young patients maintaining fertility or minimising the risk of treatment-induced malignancy may be a major reason for avoiding chemotherapy. The site of disease may also influence treatment decisions with irradiation of abdominal or cervical nodes producing greater morbidity than sites such as groin or axilla.
We have reported our experience in managing clinical stage I nodal intermediate grade non-Hodgkin's lymphoma using radiotherapy alone for non-bulky disease and combination chemotherapy for bulky disease. Patients relapsing after radiotherapy have been adequately salvaged by chemotherapy. We have excluded patients with stage II disease, mediastinal lymphoma, and extranodal sites from our series to present a more uniform patient group. We would strongly encourage other centres to present results in a similar fashion so that realistic comparisons can be made between published series.
